Abstract: The present application relates to a use of a strain of the genus Cutibacterium, a culture of the strain, or a combination thereof for prevention, amelioration, and/or treatment of inflammatory skin diseases. A composition comprising a strain of the genus Cutibacterium, a culture of the strain, or a combination thereof does not show cytotoxicity, inhibits proliferation of immune cells that cause skin inflammation, suppresses immune responses, has an antibacterial effect against acne-causing bacteria, and promotes regeneration of skin cells, thereby exhibiting excellent preventive, ameliorating, and/or therapeutic effects of inflammatory skin diseases.

Abstract: The present disclosure relates to a novel Leuconostoc mesenteroides strain.

Abstract: The present disclosure relates to compositions containing a novel Leuconostoc mesenteroides strain, a culture thereof, or a component derived therefrom for preventing, alleviating, or treating cancer or inflammation.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

Abstract: The invention provides compositions comprising flagellin polypeptides from bacterial strains and the use of such compositions in the treatment of disease.

Abstract: The present invention relates to a Faecalibacterium sp. microorganism and a composition for diagnosis or treatment of bowel diseases, comprising same.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing neurodegenerative disorders.

Abstract: The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives.

Abstract: The present disclosure proposes an apparatus for determining an intestinal microbiome index. The apparatus according to the present disclosure may: obtain test information about a biological sample of a subject from a test apparatus; determine, based on the test information, first information about the similarity of intestinal microflora, second information about a proportion of harmful intestinal microflora, third information about a proportion of beneficial intestinal microflora, and/or fourth information about the diversity of intestinal microflora; and determine an intestinal microbiome index indicating a state of intestinal microbiome of the subject based on the determined information.